IRIDEX (NASDAQ:IRIX) Issues Quarterly Earnings Results, Beats Expectations By $0.04 EPS

IRIDEX (NASDAQ:IRIX) released its earnings results on Tuesday. The medical equipment provider reported ($0.03) EPS for the quarter, topping the consensus estimate of ($0.07) by $0.04, FiscalAI reports. IRIDEX had a negative return on equity of 1,204.74% and a negative net margin of 8.42%.The business had revenue of $11.80 million during the quarter, compared to analysts’ expectations of $11.91 million.

Here are the key takeaways from IRIDEX’s conference call:

• IRIDEX said it remains on track to be cash flow positive in 2026, after delivering positive Adjusted EBITDA in 2025 and positive operating cash flow in Q4 2025.
• First-quarter revenue was $11.8 million, essentially flat year over year and above the company’s prior guidance, with strength in G6 probes offsetting weakness in retina system sales.
• The company highlighted continued momentum in its glaucoma business, including 15,500 probes sold versus 13,900 a year ago and 14% growth in Cyclo G6 product family revenue.
• Retina revenue was pressured by international regulatory delays, supply constraints, and geopolitical volatility, including deferred orders in Japan and disruptions in Asia and the Middle East.
• Management reaffirmed full-year 2026 guidance of $51 million to $53 million in revenue and expects cost savings from headquarters relocation and manufacturing transitions to support margin expansion over time.

IRIDEX Stock Performance

IRIX stock opened at $1.05 on Wednesday. The stock’s 50 day simple moving average is $1.11 and its 200 day simple moving average is $1.17. IRIDEX has a fifty-two week low of $0.87 and a fifty-two week high of $1.65. The company has a market cap of $18.27 million, a P/E ratio of -4.04 and a beta of 0.64.

Wall Street Analyst Weigh In

IRIX has been the subject of several recent analyst reports. Weiss Ratings raised IRIDEX from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Monday, May 4th. iA Financial set a $3.00 target price on shares of IRIDEX in a research note on Thursday, February 5th. Finally, Alliance Global Partners began coverage on shares of IRIDEX in a research note on Thursday, February 5th. They set a “buy” rating on the stock. One research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $3.00.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the business. Jane Street Group LLC lifted its stake in shares of IRIDEX by 93.9% in the fourth quarter. Jane Street Group LLC now owns 31,758 shares of the medical equipment provider’s stock valued at $36,000 after buying an additional 15,377 shares in the last quarter. Apexium Financial LP lifted its stake in shares of IRIDEX by 53.0% in the third quarter. Apexium Financial LP now owns 100,529 shares of the medical equipment provider’s stock valued at $116,000 after buying an additional 34,834 shares in the last quarter. Susquehanna International Group LLP increased its holdings in IRIDEX by 46.2% during the 3rd quarter. Susquehanna International Group LLP now owns 56,470 shares of the medical equipment provider’s stock worth $65,000 after purchasing an additional 17,834 shares in the last quarter. Finally, Citadel Advisors LLC increased its holdings in IRIDEX by 62.7% during the 3rd quarter. Citadel Advisors LLC now owns 109,473 shares of the medical equipment provider’s stock worth $126,000 after purchasing an additional 42,202 shares in the last quarter. Institutional investors and hedge funds own 20.10% of the company’s stock.

About IRIDEX

IRIDEX Corporation (NASDAQ: IRIX) is a medical technology company specializing in the development, manufacturing and commercialization of innovative ophthalmic laser and imaging systems. The company’s offerings focus on energy-based therapies designed to treat retinal vascular disorders, glaucoma and other ocular conditions. IRIDEX’s portfolio includes laser photocoagulation platforms, micro-pulse laser technology, and related consumable devices for use by ophthalmologists and retina specialists.

The company’s flagship products include the Cyclo G6 Glaucoma Laser System, which delivers precise, controlled micro-pulse laser therapy for patients with refractory glaucoma, and the IQ 532 Retina Laser System, designed to support minimally invasive laser treatments for diabetic retinopathy and age-related macular degeneration.